Lite Strategy (LITS) Free Cash Flow (2010 - 2026)
Lite Strategy (LITS) posted quarterly Free Cash Flow of -$1.5 million for Q1 2026, up 54.3% year-over-year from -$967591.9 in Q1 2025, and up 22.6% quarter-over-quarter from -$1.9 million in Q4 2025.
Lite Strategy (LITS) Free Cash Flow (2010 - 2026) Analysis & Trends
Lite Strategy's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 54.3% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$10.4 million (up 71.44% YoY), while the FY2025 annual figure was -$20.8 million, up 58.71% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$1.5 million, up from -$1.9 million in the prior quarter.
- The five-year high for Free Cash Flow was -$1.5 million in Q1 2026, with the low at -$18.5 million in Q3 2023.
- The 5-year median for Free Cash Flow is -$11.3 million (2023), against an average of -$9.7 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 91.25% in 2022, then surged 86.33% in 2025.
- Lite Strategy's Free Cash Flow stood at -$14.3 million in 2022, then rose by 22.53% to -$11.1 million in 2023, then surged by 66.84% to -$3.7 million in 2024, then surged by 47.38% to -$1.9 million in 2025, then grew by 22.6% to -$1.5 million in 2026.
- Business Quant data shows LITS's Free Cash Flow at -$1.5 million in Q1 2026, -$1.9 million in Q4 2025, and -$4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -1.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.49 Mn |
| Mar 31, 2026 | -1.49 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Sep 30, 2024 | -11.45 Mn |
| Sep 30, 2024 | -11.45 Mn |
| Jun 30, 2024 | -18.00 Mn |
| Jun 30, 2024 | -18.00 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -11.06 Mn |
| Dec 31, 2023 | -11.06 Mn |